Cogent Begin Period Cash Flow from 2010 to 2025
| COGT Stock | USD 6.61 0.14 2.16% |
Begin Period Cash Flow | First Reported 2017-03-31 | Previous Quarter 88.2 M | Current Value 97 M | Quarterly Volatility 85.2 M |
Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 4.8 M or Selling General Administrative of 45.4 M, as well as many indicators such as Price To Sales Ratio of 35.83, Dividend Yield of 0.0 or PTB Ratio of 3.48. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
Cogent | Begin Period Cash Flow |
Latest Cogent Biosciences' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Cogent Biosciences over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Cogent Biosciences' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cogent Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Cogent Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 65,517,332 | |
| Geometric Mean | 28,593,089 | |
| Coefficient Of Variation | 116.96 | |
| Mean Deviation | 58,708,706 | |
| Median | 41,321,000 | |
| Standard Deviation | 76,627,224 | |
| Sample Variance | 5871.7T | |
| Range | 238.2M | |
| R-Value | 0.66 | |
| Mean Square Error | 3549.4T | |
| R-Squared | 0.44 | |
| Significance | 0.01 | |
| Slope | 10,625,170 | |
| Total Sum of Squares | 88076T |
Cogent Begin Period Cash Flow History
About Cogent Biosciences Financial Statements
Cogent Biosciences shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Cogent Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Cogent Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cogent Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 53.2 M | 101.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.